home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS® (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma

June 14, 2023

From Seagen Inc.

Via Business Wire

Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating ↗

June 14, 2023

B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a

Via Benzinga

Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting ↗

June 13, 2023

Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy...

Via Benzinga

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

June 13, 2023

From Seagen Inc.

Via Business Wire

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,800 Today ↗

June 07, 2023

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $4,000 Today ↗

May 23, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

3 Undervalued Biotech Stocks to Buy Before They Blast Off ↗

June 02, 2023

Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling.

Via InvestorPlace

3 Stocks Worth Buying at 52-Week Lows

May 30, 2023

Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors

Via MarketBeat

Seagen Stockholders Approve Acquisition by Pfizer

May 30, 2023

From Seagen Inc.

Via Business Wire

Check Out What Whales Are Doing With SGEN ↗

May 18, 2023

Via Benzinga

(SGEN) - Analyzing Seagen's Short Interest ↗

May 15, 2023

Via Benzinga

$100 Invested In Seagen 5 Years Ago Would Be Worth This Much Today ↗

May 05, 2023

Via Benzinga

FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too? ↗

May 24, 2023

Should Pfizer and Seagen investors be worried?

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

May 23, 2023

Via Benzinga

Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News ↗

May 22, 2023

The pharmaceutical giant wouldn't be borrowing if it didn't have plans for how to make a tidy return.

Via The Motley Fool

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

May 19, 2023

Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.

Via MarketBeat

Topics Bonds

FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal ↗

May 17, 2023

Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)

Via Benzinga

Seagen's Return on Invested Capital Insights ↗

May 03, 2023

Via Benzinga

FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A ↗

May 16, 2023

In a rare move to block a large pharma deal, the U.S.

Via Benzinga

GDC Stock Alert: Why Is GD Culture Group Up 106% Today? ↗

May 16, 2023

GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023.

Via InvestorPlace

Why Is Guardforce AI (GFAI) Stock Up Today? ↗

May 16, 2023

Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering.

Via InvestorPlace

GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100? ↗

May 16, 2023

Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares.

Via InvestorPlace

Seagen (SGEN) Stock Falls 6% After Director Sells Shares ↗

May 16, 2023

Seagen (SGEN) stock is slipping on Tuesday after one of the company's directors sold shares worth more than $372,000 on Monday.

Via InvestorPlace

Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover ↗

May 16, 2023

Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way.

Via Investor's Business Daily

Vaccine Sales Are Falling. Should You Still Buy Pfizer? ↗

May 04, 2023

This is a transition year for Pfizer.

Via The Motley Fool

7 High-Yield Dividend Stocks to Buy and Hold Forever ↗

April 30, 2023

A stagnant market can be frustrating, but also a good time to look for high-yield dividend stocks to buy now.

Via InvestorPlace

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.

Via Investor's Business Daily

Seagen Reports First Quarter 2023 Financial Results

April 27, 2023

From Seagen Inc.

Via Business Wire

Earnings Scheduled For April 27, 2023 ↗

April 27, 2023

Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com